Tempest Therapeutics, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Tempest entered a Master Services Agreement with Factor Bioscience Inc. effective September 22, 2026, for in vivo CAR-T research support. Factor will provide lab access, equipment, training, protocols, and mRNA constructs from its Cambridge, MA facility. Tempest pays $5 million annually ($416,667/month) plus reimbursable materials and 10% project management fee. Either party may terminate with 30 days' notice; Tempest may suspend up to 3 times monthly with 14 days' notice while remaining liable for costs.
Why this rating
Contract value ($5M/year) is 16.6% of company's $30.1M market cap—meaningful absolute amount but typical R&D outsourcing. No equity dilution, debt, or operational restructuring. Board appointment of finance executive is governance positive but routine. Near-term stock impact likely muted.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.